Need help? Order a test

Developing and providing personalised cancer tests for doctors and patients

More about RGCC
Scroll down

Information for patients

We work with cancer patients to provide a range of personalised tests so you can choose the best treatment.

More patient information

Cancer tests

New methods and reliable tests to help deliver personalised treatment

RGCC CAMBISeq™

RGCC CAMBISeq (cancer analysis, mutational burden and instability sequencing) provides next generation sequencing analysis on both DNA and RNA to help predict a patient’s response to immunotherapy and to detect variants.

View test

Array comparative genomic hybridisation (aCGH) RGCC

This test identifies chromosomal abnormalities – when either part of the genetic sequence in a chromosome is deleted or added to – that might lead to cancer. It uses a technique called array CGH to identify abnormalities in a genome more clearly than traditional microscopes can. These abnormalities could be linked with parts of regions […]

View test

Immune-Frame

This test focuses on the status of a patient’s immune system. The test uses specific cellular markers, and the production of proteins called cytokines, to detect the type or types of cells that are responsible for switching a patient’s immune system on and off. Immune-Frame uses two different assays: the ELISA assay is used to […]

View test

Metastat RGCC

This test provides information, based on the detection of circulating tumour cells, about whether and where the tumour is likely to spread. Studies show that the cancer cells that have the potential to spread from the primary tumour express specific genes and proteins, or markers. These markers vary according to the organ that the tumour […]

View test

ChemoSNiP

This test relies on pharmacogenomics. This is the science of inherited variations in genes, how these inherited variations dictate a patient’s response to a drug, and the ways these variations can be used to predict whether a patient will have a good or bad response to a drug, or no response at all. ChemoSNiP tests […]

View test

Onconomics Extracts

This test provides information about the efficacy of natural biological substances or extracts on circulating tumour cells. Onconomics Extracts focuses on testing using three methods: testing for the direct effect of an anti-cancer treatment, stimulating the immune system and inhibiting proliferative signals in the cancer cells that stimulate them to grow.

View test

Onconomics Plus RGCC

This test provides information about the effect of specific anti-cancer drugs, targeted therapies and natural treatments on the cancer cells in an individual patient. The test combines a molecular and a cellular approach by incorporating two procedures: epigenetic analysis and viability assays. Onconomics Plus RGCC is based on three methods: testing for the direct effect […]

View test

Onconomics RGCC

This test provides information about the effect of specific anti-cancer drugs and targeted therapies on a single patient. The test combines a molecular and a cellular approach by incorporating two procedures: epigenetic analysis and viability assays.

View test

Oncotrail RGCC

This test provides information about the presence of circulating tumour cells, their concentration, and immunophenotype for specific types of malignancies. This test is a tailor-made test for certain cancers: such as breast cancer (for which we provide the Oncotrail RGCC for breast cancer) and prostate cancer (for which we provide Oncotrail RGCC for prostate cancer. […]

View test

Oncotrace RGCC

This test provides information about the presence of circulating tumour cells, and their concentration and immunophenotype, which may help identify their origin. It is used to provide guidance about a patient’s prognosis, and to help identify the primary tumour when this is unknown.

View test

Oncocount RGCC

This test detects the presence of circulating tumour cells, and measures their concentration in the blood. As these cells that could lead to the recurrence of a cancer, this test is useful to detect relapse early, and as a follow-up tool.

View test
See all RGCC tests

Use our ‘smart filter’ to identify which test is best for your patients

Find out more

News & events

Find out more about our latest research, trials and education days

Workskop on Cellular and Oligonucleotide therapies

On October 17th, RGCC founder and genetics pioneer Dr Ioannis Papasotiriou and members of RGCC’s scientific team hosted a workshop regarding Cellular and Oligonucleotide therapies.

Read more
webinar-berlin

Treatment protocol for cancer with unknown origin of the primary tumor.

On October 14th, RGCC’s director and members of his team, hosted an online-webinar about RGCC’s tests, and therapies. Participants had also the opportunity to watch real-time, the administration of therapies on an experimental model.

Read more
webinar-swiss

Personalised cancer treatment improves patient outcomes

Patients with advanced cancer were more likely to survive for longer or experience longer periods without disease progression if they received personalised cancer therapy, researchers at the University of California San Diego School of Medicine have found. In a recent trial, three-year survival for cancer patients receiving personalised cancer treatments was 55%, compared to 25% […]

Read more

Cancer diagnosis delays could cost thousands of lives

Delays to cancer diagnosis caused by COVID-19 could be responsible for thousands of avoidable deaths in the UK, a new report study published in The Lancet has found. In a ground-breaking new population-based modelling study, a London-based research team has attempted to calculate the impact of the coronavirus pandemic on cancer diagnosis and treatment outcomes. […]

Read more

Scientists identify new biomarker for cancer diagnosis

Scientists have identified tiny packages of materials released by tumours, called EVPs (extracellular vesicles and particles) that could be a potential biomarker for detecting several types of cancer at an early stage. In a recent study, published in the prestigious Cell journal, a US-based team have identified an exciting new biomarker that could lead to […]

Read more

Global Presence

RGCC operates in 23 countries across the world, with bases in all five continents.

Find out more